Antares signs third deal with Teva:
This article was originally published in Clinica
Executive Summary
Antares Pharma has announced its third deal with Teva Pharmaceutical Industries in less than a year. The Israeli generic drugs giant has obtained exclusive rights to market Antares Pharma's needle-free injection system with an unnamed product in the US, with launch potentially by the end of 2006 or early in 2007. Ewing, New Jersey-based Antares will receive an upfront cash payment, milestone fees, a percentage of net sales and a purchase price for each injection system sold.